HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Antiaggregation Time after Treating Bifurcations

Defining dual antiplatelet therapy (DAPT) seems a never-ending story. We go from trials showing the safety of...
solaci -
Learn More
Antiplatelet

ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty

Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual...
solaci -
Learn More
Antiplatelet

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention

Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular...
solaci -
Learn More
Other

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction

This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction...
solaci -
Learn More
Antiplatelet

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow...
solaci -
Learn More
Acute coronary syndromes

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access

Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has...
solaci -
Learn More
Antithrombotic Anticoagulants

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization

For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after...
solaci -
Learn More
Coronary disease

SOLACI-SOCIME 2018 | New Indications

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Learn More